In immunology, cytokine release syndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors such as infections and certain drugs.[3] It refers to cytokine storm syndromes (CSS)[4] and occurs when large numbers of white blood cells are activated and release inflammatory cytokines, which in turn activate yet more white blood cells. CRS is also an adverse effect of some monoclonal antibody medications, as well as adoptive T-cell therapies.[5][6] When occurring as a result of a medication, it is also known as an infusion reaction.[1]
The term cytokine storm is often used interchangeably with CRS but, despite the fact that they have similar clinical phenotype, their characteristics are different. When occurring as a result of a therapy, CRS symptoms may be delayed until days or weeks after treatment. Immediate-onset CRS is a cytokine storm,[7] although severe cases of CRS have also been called cytokine storms.[2]
^ abVidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, et al. (August 2010). "In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop". Cytokine. 51 (2): 213–5. doi:10.1016/j.cyto.2010.04.008. PMID 20471854.
^Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. (June 2018). "Cytokine release syndrome". Journal for Immunotherapy of Cancer. 6 (1): 56. doi:10.1186/s40425-018-0343-9. PMC 6003181. PMID 29907163.
^Behrens EM, Koretzky GA (June 2017). "Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era". Arthritis & Rheumatology. 69 (6): 1135–1143. doi:10.1002/art.40071. PMID 28217930. S2CID 21925082.
^Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. (July 2014). "Current concepts in the diagnosis and management of cytokine release syndrome". Blood. 124 (2): 188–95. doi:10.1182/blood-2014-05-552729. PMC 4093680. PMID 24876563.
^Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P (April 2017). "New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management". Critical Care. 21 (1): 89. doi:10.1186/s13054-017-1678-1. PMC 5391608. PMID 28407743.
^Porter D, Frey N, Wood PA, Weng Y, Grupp SA (March 2018). "Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel". Journal of Hematology & Oncology. 11 (1): 35. doi:10.1186/s13045-018-0571-y. PMC 5833070. PMID 29499750.
and 27 Related for: Cytokine release syndrome information
In immunology, cytokinereleasesyndrome (CRS) is a form of systemic inflammatory response syndrome (SIRS) that can be triggered by a variety of factors...
macrophage activation syndrome, NLRC4 macrophage activation syndrome, cytokinereleasesyndrome and sepsis. The term "cytokine storm" is often loosely...
is cytokinereleasesyndrome (CRS), a condition in which the immune system is activated and releases an increased number of inflammatory cytokines. The...
idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokinereleasesyndrome, and COVID‑19. In the European Union, tocilizumab is indicated...
administered subcutaneously. The most common side effects include cytokinereleasesyndrome, fatigue, injection site reaction, diarrhea, upper respiratory...
CD20-directed CD3 T-cell engager. The most common side effects include cytokinereleasesyndrome, muscle and bone pain, rash, and tiredness. It was approved for...
Janssen Pharmaceuticals. The most common adverse reactions include cytokinereleasesyndrome, dysgeusia, nail disorder, musculoskeletal pain, skin disorder...
by the expression of anti-inflammatory cytokines, like IL-10, rather than by the severe cytokinereleasesyndrome of pro-inflammatory mediators induced...
by intravenous infusion. The most common side effects include cytokinereleasesyndrome, rash, pyrexia (fever), pruritus (itching), fatigue (tiredness)...
treat multiple myeloma. The most common side effects include cytokinereleasesyndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened...
that secrete high amounts of inflammatory cytokines. It is classified as one of the cytokine storm syndromes. There are inherited and non-inherited (acquired)...
survival. Cytokinereleasesyndrome is another side effect and can be a function of therapeutic effectiveness. As the tumor is destroyed, it releases large...
Anakinra is also effective. Cytokinereleasesyndrome Grom AA, Mellins ED (September 2010). "Macrophage activation syndrome: advances towards understanding...
recipient. The most common adverse reactions include pyrexia, cytokinereleasesyndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections...
platelets (components that help the blood to clot), as well as cytokinereleasesyndrome (a potentially life-threatening condition that can cause fever...
occur in most patients. The most common serious side effects are cytokinereleasesyndrome (a potentially life-threatening condition that can cause fever...
of systemic therapy. The most common adverse reactions include cytokinereleasesyndrome, fatigue, musculoskeletal pain, injection site reactions, pyrexia...
by Genentech. The most common adverse reactions (≥20%) include cytokinereleasesyndrome, fatigue, rash, pyrexia, and headache. The most common grade 3...
into the recipient. The FDA label carries a boxed warning for cytokinereleasesyndrome (CRS), which is a systemic response to the activation and proliferation...
populate the bone marrow. Axicabtagene treatment carries a risk for cytokinereleasesyndrome (CRS) and neurological toxicities. Due to CD19 being a pan-B cell...
animal models of cytokine storm. As a repurposed drug, prazosin is being investigated for the prevention of cytokine storm syndrome and complications...
CAR-T treated murine model. Cytokinereleasesyndrome (CRS) Hemophagocytic lymphohistiocytosis, macrophage activation syndrome, and CRS are common side effects...
approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokinereleasesyndrome". U.S. Food and Drug Administration (FDA). 30 August 2017. Retrieved...
life-threatening chimeric antigen receptor T cell (CAR-T) associated cytokinereleasesyndrome (CRS). GM-CSF is produced by CAR-T cells upon recognition of target...
Global Information